Literature DB >> 14967735

Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart.

Juha Rutanen1, Tuomas T Rissanen, Johanna E Markkanen, Marcin Gruchala, Päivi Silvennoinen, Antti Kivelä, Antti Hedman, Marja Hedman, Tommi Heikura, Maija-Riitta Ordén, Steven A Stacker, Marc G Achen, Juha Hartikainen, Seppo Ylä-Herttuala.   

Abstract

BACKGROUND: It is unclear what is the most efficient vector and growth factor for induction of therapeutic vascular growth in the heart. Furthermore, the histological nature of angiogenesis and potential side effects caused by different vascular endothelial growth factors (VEGFs) in myocardium have not been documented. METHODS AND
RESULTS: Adenoviruses (Ad) at 2 doses (2x10(11) and 2x10(12) viral particles) or naked plasmids (1 mg) encoding LacZ control, VEGF-A165, or the mature, soluble form of VEGF-D (VEGF-D(DeltaNDeltaC)) were injected intramyocardially with the NOGA catheter system into domestic pigs. AdVEGF-D(DeltaNDeltaC) gene transfer (GT) induced a dose-dependent myocardial protein production, as measured by ELISA, resulting in an efficient angiogenic effect 6 days after the injections. Also, AdVEGF-A165 produced high gene transfer efficacy, as demonstrated with immunohistochemistry, leading to prominent angiogenesis effects. Despite the catheter-mediated approach, angiogenesis induced by both AdVEGFs was transmural, with maximal effects in the epicardium. Histologically, strongly enlarged alpha-smooth muscle actin-positive microvessels involving abundant cell proliferation were found in the transduced regions, whereas microvessel density did not change. Myocardial contrast echocardiography and microspheres showed marked increases in perfusion in the transduced areas. VEGF-D(DeltaNDeltaC) but not matrix-bound VEGF-A165 was detected in plasma after adenoviral GT. A modified Miles assay demonstrated myocardial edema resulting in pericardial effusion with the higher AdVEGF doses. All effects returned to baseline by 3 weeks. Naked plasmid-mediated GT did not induce detectable protein production or vascular effects.
CONCLUSIONS: Like AdVEGF-A165, AdVEGF-D(DeltaNDeltaC) GT using the NOGA system produces efficient transmural angiogenesis and increases myocardial perfusion. AdVEGF-D(DeltaNDeltaC) could be useful for the induction of therapeutic vascular growth in the heart.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14967735     DOI: 10.1161/01.CIR.0000115519.03688.A2

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  37 in total

Review 1.  Update on gene therapy for myocardial ischaemia and left ventricular systolic dysfunction or heart failure.

Authors:  Jerome Roncalli; Jörn Tongers; Douglas W Losordo
Journal:  Arch Cardiovasc Dis       Date:  2010-06-23       Impact factor: 2.340

Review 2.  Gene targeting in ischemic heart disease and failure: translational and clinical studies.

Authors:  Shaina R Eckhouse; Jeffrey A Jones; Francis G Spinale
Journal:  Biochem Pharmacol       Date:  2012-08-28       Impact factor: 5.858

3.  Tissue-engineered pro-angiogenic fibroblast scaffold improves myocardial perfusion and function and limits ventricular remodeling after infarction.

Authors:  J Raymond Fitzpatrick; John R Frederick; Ryan C McCormick; David A Harris; Ah-Young Kim; Jeffrey R Muenzer; Alex J Gambogi; Jing Ping Liu; E Carter Paulson; Y Joseph Woo
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-03       Impact factor: 5.209

Review 4.  Human gene therapy and imaging: cardiology.

Authors:  Joseph C Wu; Seppo Yla-Herttuala
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

5.  Vascular endothelial growth factor D is dispensable for development of the lymphatic system.

Authors:  Megan E Baldwin; Michael M Halford; Sally Roufail; Richard A Williams; Margaret L Hibbs; Dianne Grail; Hajime Kubo; Steven A Stacker; Marc G Achen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

6.  Macrophage colony-stimulating factor improves cardiac function after ischemic injury by inducing vascular endothelial growth factor production and survival of cardiomyocytes.

Authors:  Tatsuma Okazaki; Satoru Ebihara; Masanori Asada; Shinsuke Yamanda; Yoshifumi Saijo; Yasuyuki Shiraishi; Takae Ebihara; Kaijun Niu; He Mei; Hiroyuki Arai; Tomoyuki Yambe
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

7.  Assessment of myocardial blood perfusion improved by CD151 in a pig myocardial infarction model.

Authors:  Hou-juan Zuo; Zheng-xiang Liu; Xiao-chun Liu; Jun Yang; Tao Liu; Sha Wen; Dao-wen Wang; Xin Zhang
Journal:  Acta Pharmacol Sin       Date:  2008-12-15       Impact factor: 6.150

8.  Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle.

Authors:  Andrey Anisimov; Annamari Alitalo; Petra Korpisalo; Jarkko Soronen; Seppo Kaijalainen; Veli-Matti Leppänen; Michael Jeltsch; Seppo Ylä-Herttuala; Kari Alitalo
Journal:  Circ Res       Date:  2009-05-14       Impact factor: 17.367

9.  Cardiac overexpression of human VEGF(165) by recombinant Semliki Forest virus leads to adverse effects in pressure-induced heart failure.

Authors:  A E Loot; A J M Roks; D Westermann; H-D Orzechowski; C Tschöpe; J C Wilschut; R A Tio; W H van Gilst; R H Henning
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

10.  Comparison of Efficiency and Function of Vascular Endothelial Growth Factor Adenovirus Vectors in Endothelial Cells for Gene Therapy of Placental Insufficiency.

Authors:  Carlo Rossi; Mark Lees; Vedanta Mehta; Tommi Heikura; John Martin; Ian Zachary; Rebecca Spencer; Donald M Peebles; Robert Shaw; Minna Karhinen; Seppo Yla-Herttuala; Anna L David
Journal:  Hum Gene Ther       Date:  2020-11       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.